Short Interest in Sanofi (NASDAQ:SNY) Grows By 51.6%

Sanofi (NASDAQ:SNY) was the target of a large growth in short interest in the month of June. As of June 15th, there was short interest totalling 7,820,000 shares, a growth of 51.6% from the May 31st total of 5,160,000 shares. Based on an average daily trading volume, of 2,410,000 shares, the short-interest ratio is presently 3.2 days. Currently, 0.3% of the shares of the company are short sold.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Rise Advisors LLC raised its stake in Sanofi by 98.4% in the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after purchasing an additional 251 shares in the last quarter. Salem Investment Counselors Inc. bought a new position in Sanofi in the 4th quarter valued at about $27,000. Venturi Wealth Management LLC raised its position in shares of Sanofi by 163.5% in the 4th quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock valued at $27,000 after buying an additional 332 shares in the last quarter. Frazier Financial Advisors LLC bought a new stake in shares of Sanofi during the 4th quarter worth approximately $28,000. Finally, Register Financial Advisors LLC acquired a new stake in shares of Sanofi during the 1st quarter worth approximately $29,000. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Stock Performance

NASDAQ:SNY traded up $1.07 during mid-day trading on Monday, hitting $49.59. 3,045,270 shares of the stock were exchanged, compared to its average volume of 2,119,382. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. The firm’s 50-day simple moving average is $48.68 and its 200 day simple moving average is $48.57. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $55.72. The stock has a market capitalization of $125.60 billion, a price-to-earnings ratio of 24.92, a price-to-earnings-growth ratio of 1.50 and a beta of 0.59.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, April 25th. The company reported $0.96 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.96. Sanofi had a net margin of 10.52% and a return on equity of 26.25%. The company had revenue of $11.36 billion during the quarter, compared to analysts’ expectations of $11.75 billion. As a group, equities analysts anticipate that Sanofi will post 4.13 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.